ReviewSmall (Weinheim an der Bergstrasse, Germany)2026
Multivalent Aptamers: Contemporary Engineering Strategies and Biomedical Applications.
Review in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multivalent Aptamers: Contemporary Engineering Strategies and Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nucleic acid aptamers represent a distinctive class of molecular recognition elements with high binding affinity, excellent chemical stability, and low immunogenicity, making them powerful tools for diverse biomedical applications. Nevertheless, monovalent aptamers are often constrained by limited binding avidity, suboptimal pharmacokinetics, and insufficient biological activation. To address these challenges, multivalent aptamers engineered by assembling multiple units in a well-defined spatial configuration, have emerged to significantly enhance target engagement. This approach improves affinity, specificity, and functional potency, unlocking novel applications inaccessible to monovalent constructs. This review provides a comprehensive overview of recent advances in multivalent aptamer engineering. First, we outline advancements in systematic evolution of ligands by exponential enrichment (SELEX) strategies enabling the direct evolution of multivalent aptamers through rational library design and target-guided selection. Subsequently, we discuss various design approaches for constructing multivalent architectures, alongside their advantages and limitations. Finally, we highlight representative applications, including targeted delivery, therapeutic intervention, molecular imaging, and diagnostics, which capitalize on the multivalency effect to achieve superior biological outcomes in next-generation biomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.